BioCryst Pharmaceuticals Inc.
BCRX | NASDAQ
$8.86
+$0.10 (+1.14%)
Sep 22, 2026, 12:33 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 6.19 | -17.49 | -5.08 | -8.63 | -13.45 | -6.83 |
PEG Ratio | -0.02 | 0.28 | 0.45 | -0.30 | 2.44 | -0.43 |
PS Ratio | 1.87 | 3.45 | 3.47 | 7.88 | 15.78 | 69.96 |
PB Ratio | -13.74 | -3.27 | -2.53 | -7.24 | -23.19 | -64.69 |
P/FCF Ratio | 5 | -29.25 | -11.83 | -13.08 | -17.16 | -9.05 |
P/OCF Ratio | 4.96 | -29.88 | -12.10 | -13.19 | -17.45 | -9.08 |
OCF/S Ratio | 37.71 | -11.54 | -28.71 | -59.76 | -90.45 | -770.36 |
Debt / Equity Ratio | -3.68 | -1.77 | -1.81 | -2.52 | -5.55 | -14.51 |
Quick Ratio | 2.03 | 2.58 | 3.12 | 4.63 | 5.31 | 3 |
Current Ratio | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 |
Asset Turnover | 1.70 | 0.92 | 0.64 | 0.49 | 0.27 | 0.05 |
Interest Coverage | 4.32 | -0.03 | -0.96 | -1.50 | -3 | -12.05 |
Return on Equity | -221.45% | 18.68% | 49.73% | 83.88% | 172.04% | 949.09% |
Return on Assets | 51.32% | -18.12% | -43.82% | -44.93% | -31.30% | -54.62% |
Return on Invested Capital | 105.24% | -0.70% | -28.06% | -33.22% | -36.55% | -67.15% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 97.82% | 97.23% | 98.59% | 97.57% | 95.38% | 90.59% |
Net Profit Margin | 30.16% | -19.72% | -68.36% | -91.25% | -117.11% | -1.03K% |
Pretax Profit Margin | 30.56% | -19.29% | -68.26% | -90.24% | -115.68% | -1.03K% |
Operating Profit Margin | 38.98% | -0.56% | -31.29% | -54.81% | -113.08% | -981.12% |
FCF Margin | 37.43% | -11.79% | -29.36% | -60.26% | -91.97% | -773.24% |
EBITDA Margin | 39.74% | 2.84% | -35.10% | -53.12% | -77.46% | -940.74% |
Add to Watchlist
Select watchlists to add or remove BCRX